Analysis of the Effect of 25G+Minimally Invasive Vitrectomy Combined with Ranibizumab in the Treatment of Vitreoretinal Diseases
Objective:To investigate the effect of 25G+minimally invasive vitrectomy combined with ranibizumab in the treat-ment of vitreoretinal diseases.Methods:A total of 80 patients with hyperplastic vitreoretinopathy(PVR)admitted to 2022.1-2024.1 in our hospital were divided into 39 patients in the control group and 41 patients in the observation group.The control group was treated with 25G+minimally invasive vitrectomy,and the observation group used intravitreal injection of ranizzumab based on the control group.The various indexes and complication rates were compared between the two groups.Results:The operation time,edema,bleeding,and absorption time were shorter than the control group,and the intraoperative bleeding volume was less than the control group(P＜0.05);the postoperative visual acuity was higher than the control group,the central macular thickness and intraocular pressure were lower than the control group(P＜0.05);the aqueous IFN-γ,IL-6,and IL-10 were lower than the control group(P＜0.05);the complication rate was lower than the control group(P＜0.05).Conclusion:The application of 25G+minimally invasive vitrectomy combined with ranibizumab in PVR patients can effectively shorten the surgical time,improve vision,inhibit inflammatory reactions,and reduce the incidence of complica-tions.
NETL
NSTL
万方数据
